Public Citizen Takes On Propoxyphene Again, This Time Comes Out On Top
Executive Summary
The recent advisory committee review of the safety and efficacy of propoxyphene products left FDA with a quandary: the panel voted to remove propoxyphene-containing products from the market, citing little to no efficacy data, but also said their removal would be problematic
You may also be interested in...
Cardiac Risks Of Propoxyphene Raced Out Of Control As FDA Moved For Immediate Withdrawal
In deciding that the pain drug propoxyphene should come off the market, Center for Drug Evaluation and Research officials went from believing there was insufficient evidence of cardiac harm at therapeutic doses to concluding there was no way the risks of heart arrhythmia could be managed and mitigated.
Cardiac Risks Of Propoxyphene Raced Out Of Control As FDA Moved For Immediate Withdrawal
In deciding that the pain drug propoxyphene should come off the market, Center for Drug Evaluation and Research officials went from believing there was insufficient evidence of cardiac harm at therapeutic doses to concluding there was no way the risks of heart arrhythmia could be managed and mitigated.
Propoxyphene Marketing Halted By FDAAA-Required QT Safety Study
The opioid, marketed under the Darvon and Darvocet brands and in generic form, has the ignominious distinction of being the first drug pulled from the market based on results of a post-marketing safety study required under the 2007 law.